Uncommon, rare and very rare adverse events.Concurrent administration with other vaccines.Suggested intervals between previous SARS-CoV-2 infection and COVID-19 vaccination Individuals previously infected with SARS-CoV-2.Table 4: Pregnancy registry information by vaccine product.Summary table of mRNA COVID-19 booster doses by age group Immunization schedule and minimum intervals for a primary series for moderately to severely immunocompromised individuals, by COVID-19 vaccine Immunization schedule for a primary series, by COVID-19 vaccine Immunogenicity, efficacy and effectiveness.Preparations authorized for use in Canada.This information is captured in the table of updates.
Covid vaccine production schedule update#
This chapter was updated based on the following guidance from NACI: Last partial content update: June 27, 2023 June 9, 2023: Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series.
July 11, 2023: Guidance on the use of COVID-19 vaccines in the fall of 2023.September 12, 2023: Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023.This chapter has not yet been updated with the following statements from the National Advisory Committee on Immunization (NACI):
0 kommentar(er)
